PubMed Health⌕ Search

Biomedical subjects

J Zivný

Publications and source records attributed to J Zivný.

At least 19 recordsLinked to original sources
PubMed1996

[Changes in hemostasis and fibrinolysis in gestational diabetes].

BACKGROUND: The most serious complication of diabetes is the progressive development of vascular changes in which impaired hemocoagulation and fibrinolysis participate. The latter were investigated in diabetes type 1 and 2, but les is known about them in gestational diabetes (GDM). The objective of the submitted work was to assess wither these disorders occur also during GDM and to compare the assessed changes of haemostasis and fibrinolysis with findings in a) non-pregnant healthy controls (n = 58), b) healthy pregnant women (n = 41) and c) groups of pregnant women with impaired haemostasis during gestation/gestational hemorrhage (n = 15), preeclampsia (n = 22), varicosities (n = 15) and dead foetus syndrome (n = 16), but normal carbohydrate metabolism. The changes in GDM were moreover compared with changes found in diabetes type 1 and 2. METHODS AND RESULTS: In pregnant women with GDM (n = 29) which was diagnosed according to WHO criteria the following parameters were examined: number of thrombocytes, APTT, fibrinogen-Fbg (according to Clauss), euglobulin fibrinolysis-ECLT, t-PA concentration, PAI-I (Coaliza, Kabi) and by microturbidimetry the concentration of plasma proteins/orosomucoid (ORM), alpha-1-antitrypsin (A1AT), prealbumin (PREA), transferrin (TRF) and alpha-2-macroglobulin (A2M). In patients with GDM a high Fbg level was found (4.51 +/- 0.98 g/l, p<0.01) not only as compared with Fbg in non-pregnant women (2.42 +/- 0.40 g/l), Fbg in healthy pregnant women (3.63 +/- 0.70 g/l) but also Fg in other patient groups with a pathological pregnancy. In pregnant women with GDM a reduced fibrinolytic activity - ECLT (464 +/- 98 min., p<0.01) was observed as compared with the finding in non-pregnant women (273 +/- 98 min.) but also in healthy pregnant women (303 +/- 106 min.). Another important deviation as compared with findings in healthy pregnant women in GDM is the reduced value of two proteinase inhibitors: A2M (2.04 +/- 0.59 g/l vs. 2.89 +/- 0.90 g/l, p < 0.01) and A1AT (2.98 +/- 0.80 g/l vs. 3.96 +/- 0.85 g/l, p < 0.01). The rise of t-PA (Ag), PAI-1 (Ag), fibrinogen and reduction of fibrinolytic activity (longer ECLT) made the changes the haemostasis and fibrinolysis in GDM closer to findings in DM type 2 than type 1. CONCLUSIONS: In GDM a higher thrombophilia was found (higher Fbg, longer ECLT) than in other groups of pregnant women. Another pathological finding is the reduced A2M level (proteinase inhibitor but also of PDGF and interleukins) and A1AT (inhibitor of leucocytic proteinases). The authors assume that these deviations favour the development of possible vascular changes in GDM and possibly also diabetic foetopathy (reduced A2M).

Adult↗
PubMed1995

[Cytodiagnosis and premature birth in light of the Bethesda system].

1. Evaluation of cytological cervico-vaginal smears by the Bethesda system enlisted cytodiagnostics among important laboratory methods which can be used also in risk pregnancies. 2. Vaginal cytology makes it possible to test at the same time the hormonal situation during pregnancy, which reflects the placental function, and to evaluate also the vaginal biocenosis. 3. The authors provided evidence that the large number of superficial cells on the cytological smear (more than 10%) is associated with low oestriol and pregnandiol levels which are warning signs of the approaching termination of pregnancy. 4. By the action of microorganisms on the vaginal epithelium typical morphological changes develop in the cell nucleus and in the cytoplasm. By polychromatic staining also the causal agents of inflammations and infections threatening the mother and foetus are apparent. 5. The authors assume that cytological examination and evaluation according to the Bethesda system should be included in the complex of antenatal examinations also in women without clinical symptoms of premature delivery or without signs of vaginal infection.

Cervix Uteri↗
PubMed1995

[Fetal fibronectin in cervico-vaginal secretions--an indicator of incipient premature labor using a membrane immunoassay].

The objective of the investigation was to test the presence of foetal fibronectin in the cervicovaginal secretion in symptomatic pregnancies and assess the possible prediction of imminent premature delivery. Prospectively 84 pregnant women were examined who were admitted to hospital with symptoms of imminent premature delivery between the 24th and 34th week of pregnancy (more than 20 contractions per day or a cervical score higher than the critical value for the given week of gestation). The secretion was collected by means of a dacron brush from the posterior labium of the portio vaginalis uteri and examined by a single-use kit FFN (Fetal Fibronectin Membrane Immunoassay, Adeza Co.). From the total of 84 specimens of secretions examined for the presence of foetal fibronectin 32 were positive and 52 negative. Of 32 pregnant women with a positive test 19 women delivered within two weeks, 13 were discharged and the deliveries took place after the 36th week of pregnancy. In the group of 52 women with a negative result of the test 50 women were discharged and the deliveries occurred after the 36th week of gestation; only two women who remained in hospital had premature deliveries within two weeks after collection of the specimen. In no patient discharged from hospital delivery occurred before the end of the 36th week of gestation. The finding of positive foetal fibronectin can be interpreted only as an increased risk of premature delivery (positive predictive value 59.4%). A negative test has a better predictive value. If the test is negative, there is a 96.1% probability that premature delivery will not occur (negative predictive value).

Cervix Uteri↗
PubMed1993

[Ratios of surface markers (CD) on peripheral blood lymphocytes in the working-age Czech population].

The authors present an account of lymphocytic CD signs in adult men (mean age 34 years) and women (mean age 29 years) of the Czech population. Mean values and standard deviations (s.d.) are given for men/women: CD2: 79.6% (6.6)/86.4% (5.3), CD 3: 71.5% (7.4)/81.1% (7.4), CD4: 42.4% (6.3)/48.4% (8.5), %CD45RA+ v CD4+: 41.7% (14.1)/47.3% (13.9), CD5: 69.5% (7.0)/76.00% (6.5), CD8: 33.9% (9.3)/29.8% (6.8). CD10: 1.9% (1.3)/2.5% (1.6), CD11c: 8.3% (4.7)/10.9% (4.4), CD16: 8.3% (3.8)/4.4% (2.3), CD19: 11.5% (4.0)/8.8% (3.2), CD20: 14.7% (4.7)/11.3%, CD22: 10.6% (9.2)/8.9% (3.5), CD45RA: 56.7% (7.6)/61.7% (7.8), CD56: 15.1% (5.7)/16.0% (6.5), CD57: 13.7% (7.9)/8.5% (6.3), CD71: 1.9% (1.3)/3.5% (1.7) a HLA DR: 22.1% (6.4)/19.6% (7.1), DP: 16.3% (7.1)/13.5% (4.9), DQ: 10.9% (5.8)/7.2% (3.2), BJK: 2.6% (2.2)/2.1% (1.1), BJL: 1.8% (1.2)/2.1% (1.3), ratio CD4/CD8 1.35 (0.49)/1.75 (0.69). The examination were made on an apparatus FACScan (Becton Dickinson).

Adult↗
PubMed1992

[Results of surgical treatment of ovarian dysfunction].

The authors operated 155 women where ovarian dysfunction was the cause of infertility. The first group was formed by 125 women with the Stein-Leventhal syndrome, the second group was formed by 30 women with dysgenesis of the gonads, karyotype, 46,XX. In the first group 97 of the operated women (77.6%) became pregnant. In the latter group after mere resection of the gonads 45 women (36%) became pregnant. After combined therapy (surgery and hormonal therapy) 52 infertile women (41.6%) became pregnant. Twenty-eight patients (22.4%) did not become pregnant. In the second group, i.e. in the group of gonadal dysgenesis 7 of 16 women (44%) became pregnant but only in the group of sclerocystic dysgenetic gonads. None of the women with streak or hypoplastic gonads became pregnant. In gonadal dysgenesis it is important to assess the quality of the follicular apparatus. For successful surgery of the ovary it is necessary to preserve a maximum of functional tissue and to use a careful surgical technique.

Female↗
PubMed1986

Plasma beta-endorphin-like immunoreactivity during pregnancy, parturition, puerperium and in newborn.

Mean beta-endorphin-like immunoreactivity in the plasma of 10 normal women in the 10th month of pregnancy was 144.3 +/- 7.5 ng/l. During labor in 7 women its immunoreactivity was increased and peaked at the time of vaginal delivery (1 162 +/- 69 ng/l). Two hours after delivery, beta-endorphin-like immunoreactivity was significantly decreased (297 +/- 39 ng/l) and after 4 to 5 days was 155 +/- 33 ng/l. Beta-endorphin-like immunoreactivity in the cord plasma (523 +/- 30 ng/l) was significantly lower than in the mother at the time of vaginal delivery and in venous blood of newborns 24 hours post partum was 156 +/- 11 ng/l. The correlation between beta-endorphin-like immunoreactivity in the mother and the cord blood plasma was not determined. At the time of the fetal hypoxia, beta-endorphin-like immunoreactivity in the cord blood plasma was increased (2 741 ng/l). We conclude that immunoreactive beta-endorphin influences a stress reaction in the mother and fetus at the time of labor. During intra-uterine life the fetus probably produces its own immunoreactive-like beta-endorphin independently of the maternal production of this peptide.

Adult↗